Elsevier Inspires Physicians to “Be The Best Doctor You Can Be” with the 25th Edition of Goldman-Cecil Medicine at ACP 2015

The world’s most influential internal medicine resource is the fastest and best place to find authoritative, state-of-the-art clinical answers

Philadelphia, PA., – (ACP Booth #1209) April 29, 2015

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of the 25th edition of Goldman-Cecil Medicine. The new edition is launching with a ground-breaking update program that provides readers access to the most current content available in the field with the included eBook. The 25th edition will be showcased at the American College of Physicians (ACP) 2015 Internal Medicine Conference held in Boston from April 28 – May 2, 2015. At 10:30 am, Friday, May 1, Dr. Lee Goldman will be at the Elsevier booth (#1209) for a meet and greet.

“Goldman-Cecil Medicine has been compiled to provide an ideal learning tool for residents, physicians, and students as well as a valuable go-to resource for experienced healthcare professionals,” Goldman said. “It includes a powerful Expert Consult eBook platform that creates a ‘living text,’ providing continuous updates that I select and are integrated into each chapter. This ensures that the content is as current as the day the book was published.”

Since its first edition in 1927, Goldman-Cecil Medicine has been the world’s most influential internal medicine resource. The new edition includes current information on the latest research, guidelines and drug standards. Those who purchase the print edition will also receive the Expert Consult eBook version that includes an interactive Q&A section to assist medical professionals in preparing for board and maintenance of certification exams, and supplementary tools such as videos, references and illustrations.

Other key features of the 25th edition include:

  • Practical, bulleted text with easy-to-use features including flow charts and treatment boxes;
  • New chapters on global health, cancer biology and genetics, and the human microbiome in health and disease;
  • Today's most current evidence-based medicine guidelines to assist in definitive diagnosis and creation of the best treatment plans possible;
  • Focused coverage of the latest developments in biology, including the specifics of current diagnosis, therapy, and medication doses;
  • The ability to view or download content via mobile devices.

“Goldman-Cecil Medicine further establishes Elsevier as a trusted resource for medical content and world leader in relevant, robust content,” said Linda Belfus, Senior Vice President of Content, Elsevier Clinical Solutions. “The material contained in this reference has been provided by a veritable who’s who of modern medicine to help physicians and medical students be the best doctors they can be.”

Goldman-Cecil Medicine is currently available for order in print and eBook. The print copy of the book will include the Expert Consult eBook edition, which is compatible with PC, Mac and most mobile devices and eReaders, and allows readers to browse, search, and interact with the content of the book. To purchase the print version please visit www.us.elsevierhealth.com.


About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com

Media contact
Christopher Capot
Director, Corporate Relations
+1 212 633 3164